Evidence map›Paper›PMID 32651464›Full record

ArticleThe Journal of antibiotics2020

Spiropiperidyl rifabutins: expanded in vitro testing against ESKAPE pathogens and select bacterial biofilms.

Marıa-Paz Cabal, Timothy E Long, Edward Turos, Ana-Belén García, Jessie L Allen, Bridget G Budny, Lindsey N Shaw

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of antibiotics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Marıa-Paz CabalDepartamento de Química Orgánica e Inorgánica, Instituto Universitario de Quimica Organometalica "Enrique Moles", Universidad de Oviedo, C/ Julián Clavería, 8, 33006, Oviedo, Spain. pcabal@uniovi.es.
Timothy E LongDepartment of Pharmaceutical Science and Research, Marshall University School of Pharmacy, One John Marshall Drive, Huntington, WV, USA.ORCID http://orcid.org/0000-0003-0213-4726
Edward TurosDepartment of Chemistry, University of South Florida, CHE 205, 4202 E. Fowler Avenue, Tampa, FL, USA.
Ana-Belén GarcíaDepartamento de Química Orgánica e Inorgánica, Instituto Universitario de Quimica Organometalica "Enrique Moles", Universidad de Oviedo, C/ Julián Clavería, 8, 33006, Oviedo, Spain.
Jessie L AllenDepartment of Cell Biology, Microbiology and Molecular Biology, University of South Florida, Tampa, FL, USA.
Bridget G BudnyDepartment of Cell Biology, Microbiology and Molecular Biology, University of South Florida, Tampa, FL, USA.
Lindsey N ShawCenter for Drug Discovery and Innovation, University of South Florida, Tampa, FL, USA.
University of South Florida · USUniversidad de Oviedo · ESMarshall University · US

Funding

The Role and Regulation of Extracellular Proteases in Staphylococcus aureusR01AI124458 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI SHAW, LINDSEY NEIL · 2017 to 2020
$1.7M
Discovery of Disulfiram as an Anti-MRSA Antibiotic AdjuvantR15AI151970 · NIAID · MARSHALL UNIVERSITY · PI LONG, TIMOTHY EDWARD · 2020 to 2020
$434k
NIAID NIH HHS R01 AI124458NIAID NIH HHS R15 AI151970
6 · The paper itself

Abstract

The expanded microbiological evaluation of a series of rifastures, novel spiropiperidyl rifamycin derivatives, against clinically relevant ESKAPE bacteria has identified several analogs with promising in vitro bioactivities against antibiotic-resistant strains of Enterococcus faecium and Staphylococcus aureus. Thirteen of the rifastures displayed minimum inhibitory concentrations (MICs) below 1 µg/ml against the methicillin- and vancomycin-resistant forms of S. aureus and E. faecium (MRSA, VRSA, VRE). Aryl-substituted rifastures 1, 11, and 12 offered the greatest bioactivity, with MICs reaching ≤0.063 µg ml

Indexed as

Anti-Bacterial AgentsBiofilmsDrug Resistance, BacterialEnterococcus faeciumMicrobial Sensitivity TestsMolecular StructureRifabutinRifamycinsStaphylococcus aureusStructure-Activity RelationshipAnti-Bacterial AgentsRifabutinrifamycin SRifamycins

Identifiers

PMID32651464
PMCPMC7928017
OpenAlexW3040899032

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.